Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bayer HealthCare to sell Nuvelo's blood clotting agent; ends

Executive Summary

Nuvelo (develops cardiovascular and cancer candidates) licensed Bayer HealthCare exclusive rights to market its Phase III thrombolytic alfimeprase outside of the US. Nuvelo retains exclusive US development and commercialization rights.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register